However, a phase I clinical trial of PF-06650808, a Notch3-specific antibody–drug conjugate, has demonstrated a reasonable safety profile and early efficacy signs of antitumor activity in patients with advanced breast cancer [27]. This evidence concerns the gene NOTCH3 and breast carcinoma.